What international patients should know
Cancer care is one of the most serious and complex areas of medicine. For international patients, China may be relevant in several situations: China is not the right option for every cancer patient. But in selected cases, China’s leading cities have strong oncology hospitals, advanced diagnostic platforms, high-volume cancer centers, CAR-T treatment experience, and specialist pathways that may be relevant to international patients. MedVoyage China helps patients and families understand whether China may be a suitable oncology pathway.
- unclear cancer diagnosis
- need for faster imaging or pathology review
- need for molecular diagnosis
- desire for a second opinion
- interest in CAR-T treatment eligibility
- interest in proton or heavy ion therapy evaluation
- comparison of oncology treatment pathways
- treatment planning after abnormal health check results
- difficulty accessing advanced oncology care in the patient’s home country
Important Medical Note
Cancer treatment decisions must be made by qualified oncologists, surgeons, hematologists, radiation oncologists, pathologists, and other medical professionals. MedVoyage China is not a hospital and does not provide cancer diagnosis, treatment, medical advice, emergency care, or treatment recommendations. This page is for educational and coordination purposes only.
Why Consider China for Oncology Evaluation?
International patients may consider China for oncology-related care because of: The most relevant first-stage cities include: China’s oncology strength is not evenly distributed across all hospitals. For international patients, hospital and department matching is critical.
- major cancer hospitals
- high patient volume
- advanced imaging
- pathology review
- molecular diagnosis
- multidisciplinary consultation
- approved CAR-T products for selected indications
- proton and heavy ion therapy resources
- large hematology and transplant centers
- international medical departments in selected hospitals
- lower cost structure for selected services compared with many private healthcare systems overseas
- Shanghai
- Beijing
- Guangzhou
- Shenzhen
- Bo’ao Lecheng in Hainan for selected special-access pathways
What Oncology Services May Be Relevant?
Depending on the patient’s condition, oncology-related pathways in China may include: Not every patient needs every service. The first step is to clarify the medical question.
- cancer diagnosis
- imaging review
- PET-CT
- MRI / CT
- pathology review
- molecular diagnosis
- genetic testing
- tumor biomarker testing
- oncology specialist consultation
- surgery evaluation
- radiotherapy evaluation
- proton and heavy ion therapy evaluation
- CAR-T eligibility evaluation
- hematology consultation
- second opinion
- multidisciplinary consultation
Advanced Cancer Diagnosis in China
For many cancer patients, diagnosis is the foundation of treatment. A complete oncology diagnosis may require: MedVoyage helps patients prepare cancer-related records before approaching hospitals. Useful records include:
- imaging
- pathology
- staging
- biomarker testing
- molecular testing
- specialist review
- multidisciplinary discussion
- diagnosis summary
- CT / MRI / PET-CT reports
- imaging files
- pathology reports
- pathology slides or blocks if requested
- immunohistochemistry reports
- genetic testing reports
- tumor marker results
- treatment history
- surgery records
- chemotherapy or radiotherapy records
- medication list
- current symptoms
- performance status if available
CAR-T Treatment in China
CAR-T is a type of cellular therapy used for selected blood cancers. It is not a general cancer treatment. It is not suitable for every cancer patient. It is usually relevant to specific hematologic malignancies, such as certain lymphomas and multiple myeloma, depending on approved indications, disease status, prior treatment history, and specialist evaluation. China has approved CAR-T products for selected indications. These products have specific approved indications. International patients must not assume that CAR-T is available or appropriate for their case. CAR-T eligibility usually depends on: MedVoyage can help patients prepare records and explore whether a CAR-T evaluation pathway may be possible. Final eligibility decisions must be made by qualified hematology or oncology teams.
- cancer type
- pathology
- biomarker status
- prior treatment lines
- disease burden
- organ function
- infection risk
- performance status
- hospital review
- product availability
- manufacturing timeline
- cost and payment
- potential side effects
- ability to remain near the hospital for monitoring
Proton and Heavy Ion Therapy in China
Proton and heavy ion therapy are advanced forms of radiotherapy. They are not suitable for every cancer patient. They may be considered for selected tumors depending on: For international patients, proton or heavy ion therapy evaluation usually requires detailed imaging, pathology, previous treatment history, and multidisciplinary review.
- cancer type
- tumor location
- stage
- prior radiotherapy
- nearby organs at risk
- treatment goal
- patient condition
- multidisciplinary evaluation
Oncology Second Opinion in China
A second opinion can be valuable before major cancer treatment decisions. International patients may seek a second opinion in China for: A second opinion is not a guarantee that the recommendation will differ from the original plan. It is a structured way to reduce uncertainty before major decisions.
- confirming diagnosis
- reviewing pathology
- reviewing imaging
- checking staging
- comparing surgery vs radiotherapy vs systemic therapy
- exploring molecular testing
- evaluating CAR-T eligibility
- evaluating proton or heavy ion therapy suitability
- understanding whether treatment in China is realistic
Who May Consider Oncology Evaluation in China?
China may be relevant for patients who: Suitability must be confirmed by qualified medical institutions.
- have suspected cancer and need clearer diagnosis
- have confirmed cancer and need a second opinion
- need pathology review
- need molecular diagnosis
- need PET-CT or advanced imaging
- need oncology specialist evaluation
- want to evaluate CAR-T eligibility
- want to evaluate proton or heavy ion therapy suitability
- face long waiting times elsewhere
- want to compare treatment options
- have family or travel support in China
- are overseas Chinese families seeking Chinese-language medical coordination
Who May Not Be Suitable?
China may not be suitable for patients who: MedVoyage is not an emergency service and cannot guarantee hospital acceptance, treatment availability, or medical outcome.
- require emergency cancer care
- are medically unstable
- cannot travel safely
- need urgent hospitalization before arrival
- lack essential medical records
- cannot remain in China for monitoring or follow-up
- expect guaranteed CAR-T access
- expect guaranteed response or cure
- want treatment outside approved indications
- cannot manage payment or insurance requirements
Cost of Oncology and CAR-T Treatment in China
Cancer care costs vary widely. They depend on: Selected healthcare services in China may cost around 20%–50% of comparable prices in the US or Europe, depending on procedure, institution, materials, medication, and complexity. This is not a guaranteed discount. CAR-T, proton/heavy ion therapy, oncology drugs, and complex cancer treatment must be quoted case by case.
- cancer type
- diagnosis
- stage
- treatment plan
- hospital
- city
- public vs international department route
- imaging
- pathology
- molecular testing
- surgery
- radiotherapy
- proton or heavy ion therapy
- systemic therapy
- CAR-T product
- hospitalization
- ICU needs
- complications
- medication
- insurance coverage
